Med-Chemist : "Quintessential Medicinal Chemistry"
Showing posts with label
Susceptible IDH1 Mutation
.
Show all posts
Showing posts with label
Susceptible IDH1 Mutation
.
Show all posts
Friday, January 20, 2023
FDA Approves Rezlidhia (olutasidenib) for Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation
›
Rigel Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) approval of Rezlidhia (olutasidenib) capsules for the t...
›
Home
View web version
